Skip to content

Anteris Technologies Global

US · AVR #3553 by market cap Listed 2024
6.82 -0.23 -3.26%
Live - 5344 symbols - heartbeat 217s ago · 2026-10-08 08:03
Pre-market 6.85 +0.44%
After-hours 6.88 +0.88%
Market cap
664.67M
P/B
2.64
EPS
-2.55
Reader sentiment Are you bullish or bearish on AVR?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 2.64 Cheap vs history 21st percentile
5-year average -650.33 · #67 of 125 in Medical Devices
P/E ratio -3.50 Cheap vs history 26th percentile
5-year average -2.66 · forward -6.52
P/S ratio 296.46 Expensive vs history 73rd percentile
5-year average 181.68 · forward 61.39 · #134 of 136 in Medical Devices

Vs. peers Medical Devices

Company Market cap P/E (TTM) P/B Div yield
Anteris Technologies Global (AVR) 664.67M -3.50 2.64 0.00%
Abbott Laboratories (ABT) 170.84B 31.95 3.34 2.47%
Medtronic (MDT) 109.38B 21.06 2.18 3.33%
Stryker Corp (SYK) 105.64B 28.54 4.40 1.26%
Boston Scientific (BSX) 60.26B 16.83 2.42 0.00%
Edwards Lifesciences (EW) 49.44B 49.87 4.66 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value7.75 Economic moatNone UncertaintyVery High

Trading 13.7% below Morningstar's fair value estimate.

Fair value

Anteris Technologies Global Corp earns a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 12% discount to our quantitative fair value estimate of $7.75 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's balance sheet increases our estimated valuation. Low leverage mitigates financial risk, potentially boosting a firm's value. For example, the firm's current ratio of 14.2 lies in the top 10% globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our view that shares are cheap.

Conversely, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield, a core component of profitability, sits in the bottom 1% globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

Economic moat

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 08:03:19 · For reference only, not investment advice and not tailored to your situation.